Cycloserine ALS Therapy for Inhibiting TDP-43 Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) do not effectively address the aggregation of TDP-43 protein, which is associated with the onset and progression of the disease.
Innovation Solution
An agent comprising cycloserine or its salts, such as D-cycloserine, is used to inhibit TDP-43 aggregation, formulated into various dosage forms to treat or prevent ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ALS are used, then general symptom management is achieved, but TDP-43 aggregation is not effectively inhibited
Solution Approach 1:
The patent changes the chemical parameter by selecting cycloserine and its salts as the active component, which has specific biochemical properties that inhibit TDP-43 aggregation. This parameter change (molecular structure and chemical composition) enables effective inhibition of TDP-43 aggregation while being applicable to TDP-43 proteinopathy, resolving the contradiction between treatment effectiveness and disease applicability
2Reliability
If TDP-43 aggregation is inhibited, then cell death is reduced and disease progression is prevented, but the mechanism requires specific chemical properties not provided by current treatments
Solution Approach 1:
The patent specifies cycloserine and its salts with particular chemical parameters (molecular structure, solubility, stability) that enable TDP-43 aggregation inhibition. By carefully selecting and optimizing these chemical parameters, the patent achieves reliable cell death reduction while managing the complexity of the chemical formulation through focused development on specific compounds with known properties
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.